International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 7.15.2021
covid 19 scientist in research lab
drug vial booster shots with gloved hand
Is a COVID-19 Booster the Answer for Myeloma Patients?
Despite receiving vaccinations, immunocompromised individuals can develop very low levels of antibodies. France and Israel have approved a booster vaccination for the vulnerable. IMF Chairman Dr. Brian G.M. Durie says it’s time for the U.S. to do the same.
Best of ASCO 2021 Webinar banner
Register for the Best of 2021 ASCO & EHA Webinar to Learn About the Most Up-to-Date Myeloma Therapies
What’s new in myeloma research? IMF Chairman Dr. Brian G.M. Durie discusses important new findings from the 2021 American Society of Clinical Oncology (ASCO) annual meeting that took place virtually from June 4-8 this year, and from the subsequent European Hematology Association’s (EHA) annual meeting. Dr. Durie explains the latest data in approachable terms that patients and caregivers can use in their everyday care decision-making. You won’t want to miss this essential webinar. At the end of the presentation, participants will have time to ask questions.
register button
490x245 fda.png
FDA Approves DARZALEX FASPRO® in Combination with Pomalidomide and Dexamethasone for Myeloma Patients After First or Subsequent Relapse
According to a press release from Janssen Pharmaceutical Companies of Johnson & Johnson, the U.S. FDA has approved “DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor." Read the full press release now.
clinical trials papers book being held by doctor
Phase III OCEAN Study Updates Results About the Safety and Efficacy of Melphalan Flufenamide Combination Therapies
Read this press release from Oncopeptides AB to learn about “updated results and safety measures based on the head-to-head phase III OCEAN study evaluating the efficacy and safety of melphalan flufenamide plus dexamethasone versus pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma who have received 2 - 4 prior lines of therapy.”
Calling All Researchers: Submit Your Grant Applications
The Brian D. Novis Research Grants honor IMF founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2022 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to submit the applications is October 1, 2021. 
indoor of hawaii raffle winner house
Just Two Weeks Left to Win Your 10-Day Vacation in Hawaii
Enter a raffle for only $50 to win a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii, as pictured here. The winner will be able to book a vacation at the villa any time during the rest of 2021 or in 2022. The dates of the stay will be based on the winner’s availability and coordination with the property owner. The lucky raffle winner will be announced on August 1, 2021.
Enter Now Button
ask doctor durie video image covid update
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

COVID-19 FAQ #34: How can myeloma patients protect themselves against the Delta variant?
Watch Now
Clinical Trials
OCEAN Trial (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Register Now
Miracles for Myeloma Virtual Run/Walk

Watch the Replay
“Living Well with Myeloma” Webinar on Nutrition

Watch the Replay
IMF Patient and Family Webinar

Watch the Replay
M-Power Charlotte Community Workshop

Click here to see all events

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Oncopeptides Inc.,
Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page